

## **EXHIBIT 46**

GlaxoSmithKline Changes in Holdings for Named Defendants <sup>(1)</sup>

October 27, 2005 – May 21, 2007

Source: SEC Form 6-K Filings <sup>(2)</sup>; SEC Form 20-F Filings; Amended Complaint

	Holdings					Quarterly Changes								Oct. 27, 2005 – May 21, 2007	
	4Q05 <sup>(3)</sup>	1Q06	2Q06	3Q06	4Q06	1Q07	2Q07 <sup>(4)</sup>	4Q05 <sup>(3)</sup>	1Q06	2Q06	3Q06	4Q06	1Q07	2Q07 <sup>(4)</sup>	
<b>Ordinary Shares</b>															
Julian Heslop <sup>(5)</sup> Chief Financial Officer	-	-	-	-	-	-	-	34	1,643	208	200	212	11,707	244	14,248
Spouse of Julian Heslop <sup>(5)</sup>	-	-	-	-	-	-	-	0	0	7,335	0	55	63	72	7,525
Heslop Family <sup>(6)</sup>	16,885	20,528	26,071	28,271	28,536	40,308	40,624	34	1,643	7,543	200	287	11,770	316	21,773
<b>American Depositary Shares</b>															
Jean-Pierre Garnier Chief Executive Officer	225,696	226,538	228,942	227,265	250,528	251,124	251,571	34	642	404	323	23,262	597	447	25,709
David Stout President, Pharmaceutical Operations <sup>(7)</sup>	-	-	-	-	-	-	-	18	541	323	249	271	2,070	347	3,817

## Notes:

<sup>(1)</sup> Data for defendant Mr. Simon Bicknell is not available.<sup>(2)</sup> SEC Form 6-K filings reviewed include filings for purchases, sales, or dividend reinvestments from the following categories: personal holdings, share option plans, ShareReward Plan, Performance Share Plan, Company ISA, Personal Equity Plan, Mid-Term Investment Plan, Annual Investment Plan, Deferred Investment Award, US Retirement Savings, US Global Savings, US Global Savings Plan, Executive Supplemental Savings Plan, awards, and gifts.

The figures above exclude transactions related to the Performance Share Plan and the Mid-Term Investment Plan, unless otherwise stated.

<sup>(3)</sup> "4Q05" runs from October 27, 2005 through December 31, 2005.<sup>(4)</sup> "2Q07" runs from April 1, 2007 through May 21, 2007.<sup>(5)</sup> Figures include all non-dividend transactions related to the Performance Share Plan.<sup>(6)</sup> The annual increases for Mr. and Mrs. Heslop for 2006 is 10 shares lower than the increase based on SEC Form 20-F filings. Holdings from SEC Form 20-F appear to include Mr. and Mrs. Heslop; however, there is no breakdown of holdings by individual.<sup>(7)</sup> Data on holdings are not available on the SEC Form 20-F for David Stout.

## GlaxoSmithKline Transactions of American Depositary Shares

Jean-Pierre Garnier

October 27, 2005 – May 21, 2007

Source: SEC Form 6-K Filings (1): Amended Complaint

Transaction Date	Transaction Price (US\$)	Number of Shares	Transaction Amount (US\$)	Acquisition/ Disposition	Transaction Description
1/3/05	\$52.43	34	\$1,783	A	Following the re-valuation of cash held within the US Retirement Savings Plan, the notational allocation of ADSs increased by 34 shares.
1/13/06	\$51.60	89	\$4,592	A	Following the re-valuation of cash held within the US Retirement Savings Plan, the notational allocation of ADSs increased by 89 shares.
2/10/06	\$51.52	90	\$4,637	A	Following the re-valuation of cash held within the US Retirement Savings Plan, the notational allocation of ADSs increased by 90 shares.
2/24/06	\$51.10	53	\$2,708	A	Following the re-valuation of cash held within the US Retirement Savings Plan, the notational allocation of ADSs increased by 53 shares.
5/17/06	\$56.99	39	\$2,223	A	Following the re-valuation of cash held within the US Retirement Savings Plan, the notational allocation of ADSs increased by 39 shares.
8/3/06	\$53.89	50	\$2,695	A	Following the re-valuation of cash held within the US Retirement Savings Plan, the notational allocation of ADSs increased by 50 shares.
10/30/06	\$28.16	68,411	\$1,928,385	A	Exercise of options on October 30, 2006 over 68,411 ADSs granted on November 21, 1995, which would have lapsed on November 20, 2006, under the SmithKline Beecham Employee Share Option Plan 1991 at a price of \$28.159 per ADS.

## GlaxoSmithKline Transactions of American Depository Shares

Jean-Pierre Garnier

October 27, 2005 – May 21, 2007

Source: SEC Form 8-K Filings [1]; Amended Complaint

Transaction Date	Transaction Price (US\$)	Number of Shares	Transaction Amount (US\$)	Acquisition/ Disposition	Transaction Description
11/20/06	\$53.93	54	\$2,912	A	Following the re-valuation of cash held within the US Retirement Savings Plan, the notational allocation of ADSs increased by 54 shares.
1/12/07	\$53.75	92	\$4,945	A	Following the re-valuation of cash held within the US Retirement Savings Plan, the notational allocation of ADSs increased by 92 shares.
2/8/07	\$32.09	88,411	\$2,195,309	A	Exercise of options on February 8, 2007 over 88,411 ADSs granted on March 24, 1997, which would have lapsed on March 23, 2007, under the SmithKline Beecham Employee Share Option Plan 1991 at a price of \$32.09 per ADS.
2/9/07	\$56.36	88	\$4,961	A	Following the re-valuation of cash held within the US Retirement Savings Plan, the notational allocation of ADSs increased by 88 shares.
2/15/07	\$57.65	63	\$3,632	A	Following the re-valuation of cash held within the US Retirement Savings Plan, the notational allocation of ADSs increased by 63 shares.
4/12/07	\$57.07	388	\$22,128	A	Increased interest under the Annual Investment Plan feature following the re-investment of dividends paid to shareholders on April 12, 2007 at a price of \$57.07 per share.

## Note:

[1] SEC Form 8-K filings reviewed include filings for purchases, sales, or dividend reinvestments from the following categories: personal holdings, ShareReward Plan, Performance Share Plan, Company ISA, Personal Equity Plan, Mid-Term Investment Plan, Annual Investment Plan, Deferred Investment Award, US Retirement Savings Plan, US Global BuyDirect Plan, Executive Supplemental Savings Plan, awards, and gifts. The figures above exclude transactions related to the Performance Share Plan and the Mid-Term Investment Plan.

[2] The 2/13/07 transaction may be related to the exercise of options on 2/8/07 over 88,411 ADSs. \$1,100 of the 88,411 ADSs were sold on 2/8/07, the same date as the exercise of the option.



**GlaxoSmithKline Transactions of Ordinary Shares**  
**Julian Heslop and Spouse <sup>(1)</sup>**

**October 27, 2005 – May 21, 2007**

Source: SEC Form 6-K Filings (2); SEC Form 20-F Filings; Amended Complaint

Transaction Date [3]	Transaction Price (UK£)	Number of Shares	Transaction Amount (UK£)	Acquisition/ Disposition	Transaction Description
11/9/05	£15.30	16	£245	A	Shares purchased through the Company's ShareReward Plan ("the Plan") which Julian Heslop entered on October 5, 2001.
12/9/05	£14.98	108	£1,617	A	Shares purchased through the Company's ShareReward Plan ("the Plan") which Julian Heslop entered on October 5, 2001.
1/5/06	£14.98	3	£45	A	Following the re-investment of dividends paid to shareholders, share ownership increased by 108 shares.
1/5/06	£14.98	3	£45	A	Purchase of shares under a Single Company ISA.
1/31/06	£14.79	18	£266	A	Shares purchased through the Company's ShareReward Plan ("the Plan") which Julian Heslop entered on October 5, 2001.
2/8/06	£14.65	(1,025)	(£15,016)	D	Shares sold to meet tax liability following the vesting of the Performance Share Plan award.
4/6/06	£14.99	5	£75	A	Purchase of shares under a Single Company ISA.
4/6/06	£14.99	9	£135	A	Shares purchased through the Company's ShareReward Plan ("the Plan") which Julian Heslop entered on October 5, 2001.
4/27/06	£11.79	54,000	£636,860	A	Exercise of options on April 27, 2006 over 54,000 Ordinary shares granted on December 3, 2002 under the GlaxoSmithKline Share Option Plan at a price of £11.79 per share.

**GlaxoSmithKline Transactions of Ordinary Shares**  
**Julian Heslop and Spouse <sup>(1)</sup>**

**October 27, 2005 – May 21, 2007**

Source: SEC Form 6-K Filings [2]; SEC Form 20-F Filings; Amended Complaint

Transaction Date [3]	Transaction Price (US\$)	Number of Shares	Transaction Amount (US\$)	Acquisition/Disposition	Transaction Description
6/9/06	-	(7,335)	-	D	Transfer by gift of 7,335 ordinary shares to spouse. [4]
8/9/06	£14.80	16	£236	A	Shares purchased through the Company's ShareReward Plan ("the Plan") which Julian Heslop entered on October 5, 2001.
7/1/06	£15.29	4	£61	A	Purchase of shares under a Single Company ISA.
7/1/06	£15.34	16	£245	A	Shares purchased through the Company's ShareReward Plan ("the Plan") which Julian Heslop entered on October 5, 2001.
9/11/06	£14.78	16	£236	A	Shares purchased through the Company's ShareReward Plan ("the Plan") which Julian Heslop entered on October 5, 2001.
10/5/06	£14.45	9	£130	A	Shares purchased through the Company's ShareReward Plan ("the Plan") which Julian Heslop entered on October 5, 2001.
10/5/06 *	£14.44	55	£794	A	Following the re-investment of dividends paid to shareholders, share ownership increased by 55 shares.



## GlaxoSmithKline Transactions of American Depository Shares

David Stout

October 27, 2005 – May 21, 2007

Source: SEC Form 8-K Filings (1); Amended Complaint

Transaction Date	Transaction Price (US\$)	Number of Shares	Transaction Amount (US\$)	Acquisition/ Disposition	Transaction Description
11/3/05	\$52.43	16	\$839	A	Following the re-valuation of cash held within the US Retirement Savings Plan, the notational allocation of ADSs increased by 16 shares.
1/13/06	\$51.80	42	\$2,167	A	Following the re-valuation of cash held within the US Retirement Savings Plan, the notational allocation of ADSs increased by 42 shares.
2/10/06	\$51.52	43	\$2,215	A	Following the re-valuation of cash held within the US Retirement Savings Plan, the notational allocation of ADSs increased by 43 shares.
2/24/06	\$51.10	44	\$2,248	A	Following the re-valuation of cash held within the US Retirement Savings Plan, the notational allocation of ADSs increased by 44 shares.
4/6/06	\$51.87	300	\$15,538	A	Increased interest under the Annual Investment Plan feature following the re-investment of dividends paid to shareholders on April 6, 2006 at a price of \$51.87 per share.
7/6/06	\$56.39	224	\$12,651	A	Increased interest under the Annual Investment Plan feature following the re-investment of dividends paid to shareholders on July 6, 2006 at a price of \$56.39 per share.
10/5/06	\$53.85	244	\$13,185	A	Increased interest under the Annual Investment Plan feature following the re-investment of dividends paid to shareholders on October 5, 2006 at a price of \$53.85 per share.
1/4/07	\$54.72	268	\$14,704	A	Increased interest under the Annual Investment Plan feature following the re-investment of dividends paid to shareholders on January 4, 2007 at a price of \$54.72 per share.

## GlaxoSmithKline Transactions of American Depository Shares

David Stout

October 27, 2005 – May 21, 2007

Source: SEC Form 6-K Filings [1]; Amended Complaint

Transaction Date	Transaction Price (US\$)	Number of Shares	Transaction Amount (US\$)	Acquisition/ Disposition	Transaction Description
1/26/07	\$54.81	43	\$2,348	A	Following the re-valuation of cash held within the US Retirement Savings Plan, the notational allocation of ADSs increased by 43 shares.
2/8/07	\$55.87	(3,475)	(\$194,148)	D	The sale of 3,475 ADSs on February 8, 2007 at an average price of \$55.87, following the exercise of options on February 8, 2007 over 4,951 ADSs.
2/15/07	\$57.85	32	\$1,845	A	Following the re-valuation of cash held within the US Retirement Savings Plan, the notational allocation of ADSs increased by 32 shares.
3/9/07	\$55.59	122	\$6,782	A	Following the re-valuation of cash held within the US Retirement Savings Plan, the notational allocation of ADSs increased by 122 shares.
5/23/07	\$57.44	29	\$1,666	A	Following the re-valuation of cash held within the US Retirement Savings Plan, the notational allocation of ADSs increased by 29 shares.

## Note:

[1] SEC Form 6-K filings reviewed include filings for purchases, sales, or dividend reinvestments from the following categories: personal holdings, share option plans, Share Award Plan, Performance Share Plan, Company ISA, Personal Equity Plan, Mid-Term Investment Plan, Annual Investment Plan, Deferred Investment Award, US Retirement Savings Plan, US Global Buy/Sell Plan, Executive Supplemental Savings Plan, awards, and gifts. The figures above exclude transactions related to the Performance Share Plan and the Mid-Term Investment Plan.





## **EXHIBIT 46A**

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200511076k4.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending November 7, 2005

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held  
within the US Retirement Savings Plan ("The Plan"), which is notionally held in  
GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline  
plc and the under-mentioned persons on 7 November 2005 of an increase in the



notional allocation of Ordinary Share ADRs on 3 November 2005 at a price of \$52.43 per share:-

Dr J P Garnier	34
Dr T Yamada	12
Dr W Calhoun	6
Mr D Phelan	108
Dr D Pulman	1
Mr D Stout	16
Mr C Viehbacher	2
Mr J Ziegler	5
Dr R Greig	48

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary  
7 November 2005

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: November 7, 2005

By: SIMON BICKNELL

-----  
Simon Bicknell  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200601096k4.txt  
<DESCRIPTION>DIRECTION/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending January 09, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

The Administrators of the GlaxoSmithKline Executive Supplemental Savings Plan  
notified the Company and the under-mentioned persons on 9 January 2006 of  
changes in their interests in Ordinary Share ADRs arising from an increase in

\$51.32 per share:-

Dr J P Garnier	58
Dr W Calhoun	10
Dr R Greig	71
Mr D Phelan	176
Dr D Pulman	12
Mr D Stout	27
Mr C Viehbacher	3
Dr T Yamada	20

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell

Company Secretary

20 February 2006

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 20, 2006

By: VICTORIA LLEWELLYN

-----  
Victoria Llewellyn  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>



<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200602286k2.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending February 28, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held  
within the US Retirement Savings Plan ("The Plan"), which is notionally held in  
GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline  
plc and the under-mentioned persons on 28 February 2006 of an increase in the

notional allocation of Ordinary Share ADRs on 24 February 2006 at a price of \$51.10 per share:-

Dr J P Garnier	53
Mr F Calhoun	19
Dr R Greig	21
Mr D Phelan	25
Dr D Pulman	6
Mr D Stout	44
Mr C Viehbacher	8
Dr T Yamada	10

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

28 February 2006

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 28, 2006

By: VICTORIA LLEWELLYN

-----  
Victoria Llewellyn  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200604106k6.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending April 10, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

The Administrators of the GlaxoSmithKline Executive Supplemental Savings Plan notified the Company and the under-mentioned persons on 7 April 2006 of changes in their interests in Ordinary Share ADRs arising from an increase in their interests under the Annual Investment Plan feature following the re-investment of the dividend paid to shareholders on 6 April 2006 at a price of \$51.87 per share:-



Dr F Calhoun	376.350
Dr J P Garnier	365.125
Mr D Stout	299.566
Dr T Yamada	234.938

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

10 April 2006

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

Date: April 10, 2006

GlaxoSmithKline plc  
(Registrant)

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200605156k2.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending May 15, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held  
within the US Retirement Savings Plan ("The Plan"), which is notionally held in  
GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline

plc and the under-mentioned persons on 15 May 2006 of an increase in the notional allocation of Ordinary Share ADRs on 11 May 2006 at a price of \$56.99 per share:-

Dr JP Garnier	39
Dr T Yamada	16
Dr F Calhoun	9
Dr R Greig	54
Mr D Phelan	136
Dr D Pulman	10
Mr D Stout	23
Mr C Viehbacher	3

This notification relates to a transaction notified in accordance with Disclosure Rule

3.1.4R(1)(a).

S M Bicknell

Company Secretary

15 May 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: May 15, 2006

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>



<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200607106k2.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending July 10, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F ☒ Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No ☒  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

The Administrators of the GlaxoSmithKline Executive Supplemental Savings Plan  
notified the Company and the under-mentioned persons on 10 July 2006 of changes  
in their interests in Ordinary Share ADRs arising from an increase in their  
interests under the Annual Investment Plan feature following the re-investment

of the dividend paid to shareholders on 6 July 2006 at a price of \$56.39 per share:-

Dr JP Garnier	273.452
Dr F Calhoun	281.859
Dr D Pulman	14.733
Mr D Stout	224.353

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

10 July 2006

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

Date: July 10, 2006

GlaxoSmithKline plc  
(Registrant)

By: VICTORIA WHYTE

-----  
Victoria Whyte

Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>

</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200608076k4.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending August 7, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held  
within the US Retirement Savings Plan ("The Plan"), which is notionally held in  
GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline  
plc and the under-mentioned persons on 4 August 2006 of an increase in the  
notional allocation of Ordinary Share ADRs on 3 August 2006 at a price of \$53.89  
per share:-

Dr F Calhoun	10
Dr JP Garnier	50
Mr D Phelan	152
Dr D Pulman	11
Mr D Stout	25
Mr C Viehbacher	3
Dr R Greig	61

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary  
7 August 2006

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: August 7, 2006

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>



<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200610106k3.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending October 10, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brantford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

The Administrators of the GlaxoSmithKline Executive Supplemental Savings Plan notified the Company and the under-mentioned persons on 6 October 2006 of changes in their interests in Ordinary Share ADRs arising from an increase in their interests under the Annual Investment Plan feature following the re-investment of the dividend paid to shareholders on 5 October 2006 at a price of \$53.95 per share:-

Dr J-P Garnier	297.426
Dr F Calhoun	306.570
Dr D Pulman	16.025
Mr D Stout	244.023

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell

Company Secretary

10 October 2006

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: October 10, 2006

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>

</DOCUMENT>

<DOCUMENT>  
 <TYPE>6-K  
 <SEQUENCE>1  
 <FILENAME>gsk200610316k2.txt  
 <DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
 <TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
 Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
 the Securities Exchange Act of 1934

For period ending October 31, 2006

GlaxoSmithKline plc  
 (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
 (Address of principal executive offices)

Indicate by check mark whether the registrant files or  
 will file annual reports under cover Form 20-F  
 or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
 information contained in this Form is also thereby furnishing the  
 information to the Commission pursuant to Rule 12g3-2(b) under the  
 Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
 Responsibility or Connected Persons

I give below details of changes in interests in the American Depositary Shares  
 (ADSs) of GlaxoSmithKline plc in respect of the under-mentioned Director:-

<TABLE>  
 <CAPTION>  
 <S>

Dr J-P Garnier

Exercise of options on 30 October 2006 over 68,411 ADSs granted on 21  
 November 1996, which would have lapsed on 20 November 2006, under the  
 SmithKline Beecham Employee Share Option Plan 1991 at a price of \$28.159 per  
 ADS. The sale of 45,500 ADSs on 30 October 2006 at an average price of  
 \$53.12.

Following this transaction Dr Garnier's total shareholding in the Company is  
 529,769.32 ADSs, which includes 217,892 ADSs that have been earned but  
 deferred under the share programmes operated by the Company. At the price at  
 which the above options were exercised, Dr Garnier's holding is equivalent  
 to more than 16 times his annual basic salary.

</TABLE>

The Company was advised of these transactions on 31 October 2006.

This notification is in accordance with Disclosure Rule 3.1.4R(1)(b).

S M Bicknell  
Company Secretary

31 October 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: October 31, 2006

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200611086k2.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending November 08, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F ☒ Form 40-F ☐

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No ☒

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held  
within the US Retirement Savings Plan ("The Plan"), which is notionally held in  
GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline  
plc and the under-mentioned persons on 8 November 2006 of an increase in the  
notional allocation of Ordinary Share ADRs on 2 November 2006 at a price of  
\$53.93 per share:-

Dr JP Garnier	54
Dr MM Slaoui	1
Dr F Calhoun	11
Dr R Greig	68
Mr D Phelan	162
Dr D Pulman	11
Mr D Stout	27
Mr C Viehbacher	4

Following a re-valuation of the cash element of the notional investment held within the Plan, which is notionally held in GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline plc and the under-mentioned persons on 7 November 2006 of an increase in the notional allocation of Ordinary Share ADRs on 3 November 2006 at a price of \$53.30 per share:-

Dr MM Slaoui	2
Dr R Greig	3

These notifications relate to transactions notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

8 November 2006

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: November 08, 2006

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>

</DOCUMENT>



<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200701056k6.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending January 05, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

The Administrators of the GlaxoSmithKline Executive Supplemental Savings Plan notified the Company and the under-mentioned persons on 5 January 2007 of changes in their interests in Ordinary Share ADRs arising from an increase in their interests under the Annual Investment Plan feature following the re-investment of the dividend paid to shareholders on 4 January 2007 at a price of \$54.72 per share:-

Dr JP Garnier	327.53
Dr F Calhoun	337.60
Dr D Pulman	17.65
Mr D Stout	268.72

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell

Company Secretary

5 January 2007  
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 05, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte

Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200701166k.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending January 16, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held  
within the US Retirement Savings Plan ("The Plan"), which is notionally held in

GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline plc and the under-mentioned persons on 15 January 2007 of an increase in the notional allocation of Ordinary Share ADRs on 12 January 2007 at a price of \$53.75 per share:-

Dr J-P Garnier	92
Dr M M Slaoui	8
Mrs C Bruck Slaoui	2
Dr F Calhoun	17
Dr R G Greig	17
Mr D Phelan	20
Dr D Pulman	6
Mr D Stout	44
Mr C Viehbacher	8

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

16 January 2007

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 16, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200701296k4.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending January 29, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No ☒

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held

within the US Retirement Savings Plan ("The Plan"), which is notionally held in GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline plc and the under-mentioned person(s) on 29 January 2007 of an increase in the notional allocation of Ordinary Share ADRs on 26 January 2007 at a price of \$54.61 per share:-

Dr J P Garnier	91
Dr M M Slaoui	8
Mrs C Bruck Slaoui	3
Dr F Calhoun	17
Dr R G Greig	20
Mr D Phelan	21
Dr D Pulman	7
Mr D Stout	43
Mr C Viehbacher	8

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).

S M Bicknell  
Company Secretary

29 January 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 29, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte

Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>



<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200702096k3.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending February 9, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in interests in the Ordinary shares and American  
Depositary Shares (ADSs) of GlaxoSmithKline plc in respect of the  
under-mentioned Directors, Persons Discharging Managerial Responsibility and  
Connected Persons:-

Dr J-P Garnier      Exercise of options on 8 February 2007 over 68,411 ADSs  
granted on 24 March 1997, which would have lapsed on 23

March 2007, under the SmithKline Beecham Employee Share Option Plan 1991 at a price of \$32.09 per ADS.

The sale of 51,100 ADSs on 8 February 2007 at an average price of \$55.81.

Following this transaction Dr Garnier's total shareholding in the Company is 556,198 ADSs, which includes 248,448 ADSs that have been earned but deferred under the share programmes operated by the Company. At the price at which the above options were exercised, Dr Garnier's holding is equivalent to more than 17 times his annual basic salary.

Mr J S Heslop

Purchase of 10,000 Ordinary shares on 9 February 2007 at a price of GBP14.51 per share.

Following this transaction Mr Heslop's total shareholding in the Company is 42,204 Ordinary shares. At the price at which the above shares were purchased, Mr Heslop's holding is equivalent to more than 1.5 times his annual basic salary.

Mr D Phelan

Exercise of options on 8 February 2007 over 54,623 ADSs granted on 13 November 1997, which would have lapsed on 12 November 2007, under the SmithKline Beecham Employee Share Option Plan 1991 at a price of \$40.54 per ADS and over 95,000 ADSs granted on 3 December 2002 under the GlaxoSmithKline Employee Share Option Plan at a price of \$37.25 per ADS.

The sale of 149,623 ADSs on 8 February 2007 at an average price of \$55.81.

Mr D Stout

Exercise of options on 8 February 2007 over 4,951 ADSs granted on 24 March 1997, which would have lapsed on 23 March 2007, under the SmithKline Beecham Employee Share Option Plan 1991 at a price of \$32.09 per ADS.

The sale of 3,475 ADSs on 8 February 2007 at an average price of \$55.87.

The Company was advised of these transactions on 8 and 9 February 2007.

This notification is in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

9 February 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the

undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 9, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>

</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200702136k6.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending February 13, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held  
within the US Retirement Savings Plan ("The Plan"), which is notionally held in  
GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline  
plc and the under-mentioned persons on 12 February 2007 of an increase in the  
notional allocation of Ordinary Share ADRs on 9 February 2007 at a price of

\$56.38 per share:-

Dr JP Garnier	88
Dr M M Slaoui	62
Mrs C Bruck Slaoui	2
Dr R G Greig	18
Mr W Louv	4
Mr D Phelan	19
Dr D Pulman	6
Mr D Stout	42
Mr C Viehbacher	7

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell

Company Secretary

13 February 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 13, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>

</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200702136k4.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending February 13, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in interests in the Ordinary shares and American  
Depositary Shares (ADSs) of GlaxoSmithKline plc in respect of the



under-mentioned Directors and Persons Discharging Managerial Responsibility:-

Dr J-P Garnier      Sale of 17,411 Ordinary Share ADRs on 13 February 2007 at a price of \$57.37 per ADR. Following this transaction Dr Garnier's total shareholding in the Company remains equivalent to more than 17 times his annual basic salary.

Mr R Bondy      Exercise on 13 February 2007 of 3,620 SmithKline Beecham UK Senior Executive Bonus Investment Rights granted on 20 March 2000 under the SmithKline Beecham Bonus Investment Plan. Sale of 1,466 shares at a price of GBP14.65 per share. Mr Bondy is retaining the 2,154 remaining shares resulting from this exercise.

The Company was advised of these transactions on 13 February 2007.

Mr J Clarke      Exercise of nil-price options on 12 February 2007 over 8,103 Ordinary shares granted on 13 February 2003 under the SmithKline Beecham Mid-Term Incentive Plan ("the MTIP"), resulting from the deferral of an award made under the MTIP on 24 November 1999.

Sale of 3,323 Ordinary shares at a price of GBP14.63 per share. Mr Clarke is retaining the 4,780 remaining shares resulting from this exercise.

The Company was advised of these transactions on 12 February 2007.

This notification is in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).

S M Bicknell  
Company Secretary

13 February 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 13, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200702166k6.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending February 16, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held  
within the US Retirement Savings Plan ("The Plan"), which is notionally held in

GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline plc and the under-mentioned persons on 16 February 2007 of an increase in the notional allocation of Ordinary Share ADRs on 15 February 2007 at a price of \$57.65 per share:-

Dr JP Garnier	63
Dr M M Slaoui	2
Dr R G Greig	76
Mr W Louv	5
Mr D Phelan	184
Dr D Pulman	13
Mr D Stout	32
Mr C Viehbacher	4

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

16 February 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 16, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200703056k4.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending March 05, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held  
within the US Retirement Savings Plan ("The Plan"), which is notionally held in

GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline plc and the under-mentioned persons on 2 March 2007 of:

(i) An increase in the notional allocation of Ordinary Share ADRs on 23 February 2007 at a price of \$56.92 per share:-

Dr JP Garnier	35
Dr M M Slaoui	7
Mrs C Bruck Slaoui	3
Dr R G Greig	21
Mr W Louv	5
Dr D Pulman	6
Mr D Stout	42
Mr C Viehbacher	8

(ii) A decrease in the notional allocation of Ordinary Share ADRs on 9 February 2007 at a price of \$56.38 per share:-

Dr M M Slaoui	54
---------------	----

(iii) A decrease in the notional allocation of Ordinary Share ADRs on 15 February 2007 at a price of \$57.65 per share:-

Dr M M Slaoui	1
---------------	---

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell

Company Secretary

5 March 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: March 05, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>



<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200704136k4.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending April 13, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

The Administrators of the GlaxoSmithKline Executive Supplemental Savings Plan notified the Company and the under-mentioned persons on 13 April 2007 of changes in their interests in Ordinary Share ADRs arising from an increase in their interests under the Annual Investment Plan feature following the re-investment of the dividend paid to shareholders on 12 April 2007 at a price of \$57.07 per share:-

Dr JP Garnier	387.74
Dr D Pulman	20.89
Mr D Stout	318.12

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

13 April 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: April 13, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200705096k2.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending May 09, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held  
within the US Retirement Savings Plan ("The Plan"), which is notionally held in  
GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline  
plc and the under-mentioned persons on 9 May 2007 of:

- (i) An increase in the notional allocation of Ordinary Share ADRs on 3 May 2007

at a price of \$57.44 per share:-

Dr JP Garnier	59
Dr M M Slaoui	1
Mrs C Bruck Slaoui	1
Dr R G Greig	72
Mr W C Louv	5
Dr D Pulman	12
Mr D M Stout	29
Mr C Viehbacher	4

The Administrators of the Plan further notified GlaxoSmithKline plc and the under-mentioned persons on 9 May 2007 of

(i) An increase in the notional allocation of Ordinary Share ADRs on 4 May 2007 at a price of \$57.90 per share:-

Mrs C Bruck Slaoui	3
Dr R G Greig	1

This notification relates to transactions notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell

Company Secretary

9 May 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: May 09, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>

</DOCUMENT>

## **EXHIBIT 46B**

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200511096k2.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending November 09, 2005

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No ☒

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons  
Discharging Managerial Responsibility or Connected Persons in the Ordinary  
Shares of GlaxoSmithKline plc in respect of the undermentioned persons arising  
from the purchase of Ordinary Shares at a price of GBP15.30 per Ordinary Share  
on 9 November 2005 through the Company's ShareReward Plan ("the Plan") which the

under-mentioned persons entered on 5 October 2001:

Mr J S Heslop	Acquisition of 8 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 8 Ordinary Shares under the matching element of the Plan (Company contribution)
Mr R Bondy	Acquisition of 8 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 8 Ordinary Shares under the matching element of the Plan (Company contribution)
Mr A P Witty	Acquisition of 8 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 8 Ordinary Shares under the matching element of the Plan (Company contribution)
Mrs J V Younger	Acquisition of 8 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 8 Ordinary Shares under the matching element of the Plan (Company contribution)

The above-mentioned persons and the Company were advised of this information on 9 November 2005.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary  
9 November 2005

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: November 09, 2005

By: Simon Bicknell

-----  
Simon Bicknell  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>



<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200512126k2.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending December 12, 2005

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons  
Discharging Managerial Responsibility or Connected Persons in the Ordinary

Shares of GlaxoSmithKline plc in respect of the undermentioned persons arising from the purchase of Ordinary Shares at a price of GBP14.40 per Ordinary Share on 9 December 2005 through the Company's ShareReward Plan ("the Plan") which the under-mentioned persons entered on 5 October 2001:

Mr J S Heslop	Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)
Mr R Bondy	Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)
Mr A P Witty	Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)
Mrs J V Younger	Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

The above-mentioned persons and the Company were advised of this information on 12 December 2005.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).

S M Bicknell  
Company Secretary  
12 December 2005

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: December 12, 2005

By: VICTORIA LLEWELLYN

-----  
Victoria Llewellyn  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>

</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200601096k.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending January 09 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in interests in the Ordinary Shares of  
GlaxoSmithKline plc in respect of the under-mentioned persons, arising from the  
purchase of Ordinary Shares on 5 January 2006 under a Single Company ISA at a  
price of GBP14.98 per Ordinary Share:

Mr J S Heslop

3

The Company and the above named persons were advised of this information on 6 January 2006.

This notification relates to a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(b).

S M Bicknell

Company Secretary

9 January 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 09 2006

By: VICTORIA LLEWELLYN

-----  
Victoria Llewellyn  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>

</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200601096k3.txt  
<DESCRIPTION>DIRECDTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending January 09, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons  
Discharging Managerial Responsibility or Connected Persons in the Ordinary  
Shares of GlaxoSmithKline plc in respect of the under-mentioned persons arising

from the purchase of Ordinary Shares at a price of GBP15.01 per Ordinary Share on 5 January 2006 through the Company's ShareReward Plan ("the Plan") which the under-mentioned persons entered on 5 October 2001:

<TABLE>	
<CAPTION>	
<S>	<C>
Mr J S Heslop	Acquisition of 7 Ordinary Shares under the Dividend Reinvestment element of the Plan
Mr R Bondy	Acquisition of 7 Ordinary Shares under the Dividend Reinvestment element of the Plan
Dr D Pulman	Acquisition of 4 Ordinary Shares under the Dividend Reinvestment element of the Plan
Mr C Viehbacher	Acquisition of 2 Ordinary Shares under the Dividend Reinvestment element of the Plan
Mrs J V Younger	Acquisition of 7 Ordinary Shares under the Dividend Reinvestment element of the Plan
Mr A P Witty	Acquisition of 7 Ordinary Shares under the Dividend Reinvestment element of the Plan

</TABLE>

The Company and the above-mentioned persons were advised of this information on 6 January 2006.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell

Company Secretary

9 January 2006  
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 09, 2006

By: VICTORIA LLEWELLYN

-----  
Victoria Llewellyn  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>



</DOCUMENT>



<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200601096k2.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending January 09 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of an increase in interests in the Ordinary Shares of  
GlaxoSmithKline plc in respect of the personal holdings of the under-mentioned  
persons at a price of GBP14.976 per Ordinary Share, following the re-investment  
of the dividend paid to shareholders on 5 January 2006.

Mr R Bondy	160
Mr J Heslop	108
Mrs C Witty	215
Mrs C Pulman	11
Dr D Pulman	57

The Company and the above named persons were advised of this information on 6 January 2006.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

9 January 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 09 2006

By: VICTORIA LLEWELLYN

-----  
Victoria Llewellyn  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200601126k3.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending January 12, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons  
Discharging Managerial Responsibility or Connected Persons in the Ordinary  
Shares of GlaxoSmithKline plc in respect of the undermentioned persons arising  
from the purchase of Ordinary Shares at a price of GBP14.79 per Ordinary Share  
on 11 January 2006 through the Company's ShareReward Plan ("the Plan") which the

under-mentioned persons entered on 5 October 2001:

Mr J S Heslop	Acquisition of 8 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 8 Ordinary Shares under the matching element of the Plan (Company contribution)
Mr R Bondy	Acquisition of 8 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 8 Ordinary Shares under the matching element of the Plan (Company contribution)
Mr A P Witty	Acquisition of 8 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 8 Ordinary Shares under the matching element of the Plan (Company contribution)
Mrs J V Younger	Acquisition of 8 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 8 Ordinary Shares under the matching element of the Plan (Company contribution)

The above-mentioned persons and the Company were advised of this information on 12 January 2006.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).

S M Bicknell  
Company Secretary  
12 January 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 12, 2006

By: VICTORIA LLEWELLYN  
-----  
Victoria Llewellyn  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200602136k3.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending February 13, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F ☒ Form 40-F ☐  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No ☒  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons  
Discharging Managerial Responsibility or Connected Persons in the Ordinary  
Shares of GlaxoSmithKline plc in respect of the under-mentioned persons arising  
from the purchase of Ordinary Shares at a price of GBP14.79 per Ordinary Share  
on 9 February 2006 through the Company's ShareReward Plan ("the Plan") which the  
under-mentioned persons entered on 5 October 2001:



Mr J S Heslop Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

Mr R Bondy Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

Mrs J V Younger Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

Mr A P Witty Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

The Company and the above-mentioned persons were advised of this information on 10 February 2006.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4 R (1) (a) and 3.1.4 R (1) (b).

S M Bicknell  
Company Secretary

13 February 2006

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 13, 2006

By: VICTORIA LLEWELLYN

-----  
Victoria Llewellyn  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200602246k3.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending February 24, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Vesting of Performance Share Plan Award

The three year performance period for the Performance Share Plan Awards granted  
on 3 December 2002, commenced on 1 January 2003 and came to an end on 31  
December 2005.

The Remuneration Committee of the Board of GlaxoSmithKline plc considered the  
performance achieved during this period and determined that 50% of these Awards  
would vest on 23 February 2006.

There were two performance conditions attached to this award. The first  
condition compared GlaxoSmithKline's total shareholder return (TSR) with the TSR  
of companies in the FTSE 100 index. For any of the awards to vest under this  
condition, GlaxoSmithKline had to rank at least 50th against the index  
companies. None of the awards subject to this condition vested. The second  
condition, which applied to the balance of the award, was achieved in full. The  
condition required GlaxoSmithKline's business performance earnings per share

growth, excluding currency and exceptional items, to be at least nine percentage points more than the increase in the UK Retail Price Index over the three year performance period.

Details of the changes in the interests of the following Executive Directors over Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc are given below.

<TABLE>  
<CAPTION>  
<S>

	<C> Final award of Shares/ADSs	<C> ADSs	<C> Shares/ADSs sold to meet tax liability	<C> Price at which Shares/ ADSs sold
Dr JP Garnier*	Shares	ADSs	0	-
Mr J S Heslop	2,500	35,000	1,025 shares	GBP14.65
Dr T Yamada		10,000	4,119 ADSs	\$51.3499

</TABLE>

\*Dr Garnier has elected to defer his award until his retirement.

The Company and the Executive Directors were informed of these changes on 23 February 2006.

S M Bicknell  
Company Secretary

24 February 2006

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 24, 2006

By: VICTORIA LLEWELLYN

-----  
Victoria Llewellyn  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200603106k3.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending March 10, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons  
Discharging Managerial Responsibility or Connected Persons in the Ordinary  
Shares of GlaxoSmithKline plc in respect of the under-mentioned persons arising  
from the purchase of Ordinary Shares at a price of GBP15.67 per Ordinary Share  
on 9 March 2006 through the Company's ShareReward Plan ("the Plan") which the

under-mentioned persons entered on 5 October 2001:

Mr J S Heslop	Acquisition of 8 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 8 Ordinary Shares under the matching element of the Plan (Company contribution)
Mr R Bondy	Acquisition of 8 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 8 Ordinary Shares under the matching element of the Plan (Company contribution)
Mr A P Witty	Acquisition of 8 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 8 Ordinary Shares under the matching element of the Plan (Company contribution)
Mrs J V Younger	Acquisition of 8 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 8 Ordinary Shares under the matching element of the Plan (Company contribution)

The Company and the above-mentioned persons were advised of this information on 10 March 2006.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

10 March 2006

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: March 10, 2006

By: VICTORIA LLEWELLYN  
-----  
Victoria Llewellyn  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200604106k5.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending April 10, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in interests in the Ordinary Shares of  
GlaxoSmithKline plc in respect of the under-mentioned person, arising from the  
purchase of Ordinary Shares on 6 April 2006 under a Single Company ISA at a  
price of GBP 14.99 per Ordinary Share:

Mr J Heslop

5

The Company and the above named person were advised of this information on 7 April 2006.

This notification relates to a transaction notified in accordance with Disclosure Rule 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

10 April 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: April 10, 2006

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>



<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200604106k3.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending April 10, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons  
Discharging Managerial Responsibility or Connected Persons in the Ordinary  
Shares of GlaxoSmithKline plc in respect of the under-mentioned person(s)  
arising from the purchase of Ordinary Shares at a price of GBP 14.99 per  
Ordinary Share on 6 April 2006 through the Company's ShareReward Plan ("the  
Plan") which the under-mentioned persons entered on 5 October 2001:

Mr J S Heslop	Acquisition of 9 Ordinary Shares under the Dividend Reinvestment element of the Plan
Mr R Bondy	Acquisition of 9 Ordinary Shares under the Dividend Reinvestment element of the Plan
Dr D Pulman	Acquisition of 7 Ordinary Shares under the Dividend Reinvestment element of the Plan
Mr C Viehbacher	Acquisition of 3 Ordinary Shares under the Dividend Reinvestment element of the Plan
Mr A P Witty	Acquisition of 9 Ordinary Shares under the Dividend Reinvestment element of the Plan
Mrs J V Younger	Acquisition of 9 Ordinary Shares under the Dividend Reinvestment element of the Plan

The Company and the above-mentioned persons were advised of this information on 7 April 2006.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

10 April 2006

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: April 10, 2006

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200604106k4.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending April 10, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of an increase in interests in the Ordinary Shares of  
GlaxoSmithKline plc in respect of the personal holdings of the under-mentioned  
persons at a price of GBP 14.89 per Ordinary Share, following the re-investment  
of the dividend paid to shareholders on 6 April 2006.

Mr R Bondy	259
Mr J Heslop	162

Mrs C Pulman	15
Dr D Pulman	80
Mr A Witty	1
Mrs C Witty	305

The Company and the above named persons were advised of this information on 7 April 2006.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).

S M Bicknell  
Company Secretary

10 April 2006

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: April 10, 2006

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200604136k2.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending April 13, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons  
Discharging Managerial Responsibility or Connected Persons in the Ordinary  
Shares of GlaxoSmithKline plc in respect of the under-mentioned persons arising  
from the purchase of Ordinary Shares at a price of GBP14.93 per Ordinary Share

on 11 April 2006 through the Company's ShareReward Plan ("the Plan") which the under-mentioned persons entered on 5 October 2001:

Mr R Bondy

Acquisition of 8 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 8 Ordinary Shares under the matching element of the Plan  
(Company contribution)

Mr J S Heslop

Acquisition of 8 Ordinary Shares under the partnership element of the Plan  
(personal contribution)

Acquisition of 8 Ordinary Shares under the matching element of the Plan  
(Company contribution)

Mr A P Witty

Acquisition of 8 Ordinary Shares under the partnership element of the Plan  
(personal contribution)

Acquisition of 8 Ordinary Shares under the matching element of the Plan  
(Company contribution)

Mrs J V Younger

Acquisition of 8 Ordinary Shares under the partnership element of the Plan  
(personal contribution)

Acquisition of 8 Ordinary Shares under the matching element of the Plan  
(Company contribution)

The Company and the above-mentioned persons were advised of this information on 12 April 2006.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).

S M Bicknell  
Company Secretary

13 April 2006

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: April 13, 2006

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>

</DOCUMENT>



<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200604286k3.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending April 28, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F ☒ Form 40-F ☐

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No ☒

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in interests in the Ordinary shares of  
GlaxoSmithKline plc in respect of the under-mentioned Director:-

Mr J S Heslop

Exercise of options on 27 April 2006 over 54,000

Ordinary shares granted on 3 December 2002 under the GlaxoSmithKline Share Option Plan at a price of GBP11.79 per share. The sale of 46,665 shares on 27 April 2006 at a price of GBP15.41 to meet the resulting cost of exercise and tax.

Following this transaction Mr Heslop's total shareholding in the Company has increased by 7,335 shares to 19,896.32 shares.

The Company was advised of this transaction on 27 April 2006.

This notification is in accordance with Disclosure Rule 3.1.4R(1)(b).

Mrs J Younger

Exercise of options on 27 April 2006 over 6,892 Ordinary shares granted on 13 August 1997 under the Glaxo Wellcome International Share Option Scheme at a price of GBP12.75 per share. Exercise of options on 27 April 2006 over 45,000 Ordinary shares granted on 3 December 2002 under the GlaxoSmithKline Share Option Plan at a price of GBP11.79 per share.

The sale of 53,298 shares on 27 April 2006 at an average price of GBP15.21.

The Company was advised of these transactions on 28 April 2006.

Mr R Bondy

The transfer by gift of 2,880 Ordinary shares in GlaxoSmithKline plc on 27 April 2006.

The Company was advised of this transaction on 27 April 2006.

These notifications are in accordance with Disclosure Rule 3.1.4R(1)(a).

S M Bicknell  
Company Secretary

28 April 2006

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: April 28, 2006

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>

</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200606096k2.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending June 09, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons  
Discharging Managerial Responsibility or Connected Persons in the Ordinary  
Shares of GlaxoSmithKline plc.

Mr J S Heslop

The transfer by gift on 6 June 2006 of 7,335

Ordinary shares in GlaxoSmithKline plc to Mrs Heslop.

The Company was advised of this transaction on 9 June 2006.

This notification relates to a transaction notified in accordance with Disclosure Rule 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

9 June 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: June 09, 2006

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200606156k2.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending June 15, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F ☒ Form 40-F ☐

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes ☐ No ☒

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons  
Discharging Managerial Responsibility or Connected Persons in the Ordinary  
Shares of GlaxoSmithKline plc in respect of the undermentioned persons arising  
from the purchase of Ordinary Shares at a price of GBP14.90 per Ordinary Share  
on 09 June 2006 through the Company's ShareReward Plan ("the Plan") which the  
undermentioned persons entered on 5 October 2001:

11/28/07

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200607106k3.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending July 10, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in interests in the Ordinary Shares of  
GlaxoSmithKline plc in respect of the under-mentioned persons, arising from the  
purchase of Ordinary Shares on 6 July 2006 under a Single Company ISA at a price  
of GBP15.29 per Ordinary Share:



Mr J Heslop  
Mr A Witty

4  
3

The Company and the above named persons were advised of this information on 10 July 2006.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b) .

S M Bicknell  
Company Secretary

10 July 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: July 10, 2006

By: VICTORIA WHYTE

-----  
Victoria Whyte

Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200607106k6.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending July 10, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No ☒

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons  
Discharging Managerial Responsibility or Connected Persons in the Ordinary  
Shares of GlaxoSmithKline plc in respect of the under-mentioned persons arising  
from the purchase of Ordinary Shares at a price of GBP15.26 per Ordinary Share

on 6 July 2006 through the Company's ShareReward Plan ("the Plan") which the under-mentioned persons entered on 5 October 2001:

Mr J S Heslop	Acquisition of 8 Ordinary Shares under the Dividend Reinvestment element of the Plan
Mr R Bondy	Acquisition of 8 Ordinary Shares under the Dividend Reinvestment element of the Plan
Mr D Learmouth	Acquisition of 8 Ordinary Shares under the Dividend Reinvestment element of the Plan
Dr D Pulman	Acquisition of 5 Ordinary Shares under the Dividend Reinvestment element of the Plan
Mr C Viehbacher	Acquisition of 2 Ordinary Shares under the Dividend Reinvestment element of the Plan
Mr A P Witty	Acquisition of 8 Ordinary Shares under the Dividend Reinvestment element of the Plan

The Company and the above-mentioned persons were advised of this information on 7 July 2006.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

10 July 2006

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: July 10, 2006

By: VICTORIA WHYTE

-----  
Victoria Whyte

Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200607106k.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending July 10, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No ☒

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of an increase in interests in the Ordinary Shares of  
GlaxoSmithKline plc in respect of the personal holdings of the under-mentioned  
persons at a price of GBP15.322 per Ordinary Share, following the re-investment  
of the dividend paid to shareholders on 6 July 2006.

Mr J Heslop	136
Mr R Bondy	217
Mr D Learmouth	27
Dr D Pulman	117
Mrs C Pulman	11
Mr A Witty	18
Mrs C Witty	236

The Company and the above named persons were advised of this information on 7 July 2006.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

10 July 2006

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: July 10, 2006

By: VICTORIA WHYTE

-----  
Victoria Whyte

Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk2006071362.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending July 13, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons  
Discharging Managerial Responsibility or Connected Persons in the Ordinary  
Shares of GlaxoSmithKline plc in respect of the undermentioned persons arising  
from the purchase of Ordinary Shares at a price of GBP15.34 per Ordinary Share  
on 11 July 2006 through the Company's ShareReward Plan ("the Plan") which the  
undermentioned persons entered on 5 October 2001:

Mr J S Heslop      Acquisition of 8 Ordinary Shares under the partnership  
                         element of the Plan (personal contribution)

                         Acquisition of 8 Ordinary Shares under the matching element  
                         of the Plan (Company contribution)

Mr R Bondy      Acquisition of 8 Ordinary Shares under the partnership  
                         element of the Plan (personal contribution)

                         Acquisition of 8 Ordinary Shares under the matching element  
                         of the Plan (Company contribution)

Mr D Learmouth      Acquisition of 8 Ordinary Shares under the partnership  
                         element of the Plan (personal contribution)

                         Acquisition of 8 Ordinary Shares under the matching element  
                         of the Plan (Company contribution)

Mr A P Witty      Acquisition of 8 Ordinary Shares under the partnership  
                         element of the Plan (personal contribution)

                         Acquisition of 8 Ordinary Shares under the matching element  
                         of the Plan (Company contribution)

The above named individuals and the Company were advised of this information on  
12 July 2006.

This notification relates to a transaction notified in accordance with  
Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).

S M Bicknell  
Company Secretary

13 July 2006

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the  
registrant has duly caused this report to be signed on its behalf by the  
undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: July 13, 2006

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200608106k3.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending August 10, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons  
Discharging Managerial Responsibility or Connected Persons in the Ordinary  
Shares of GlaxoSmithKline plc in respect of the undermentioned persons arising  
from the purchase of Ordinary Shares at a price of GBP14.22 per Ordinary Share  
on 9 August 2006 through the Company's ShareReward Plan ("the Plan") which the



undermentioned persons entered on 5 October 2001:

Mr J S Heslop	Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)
Mr R Bondy	Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)
Mr D Learmouth	Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)
Mr A P Witty	Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

The above named individuals and the Company were advised of this information on 10 August 2006.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).

S M Bicknell  
Company Secretary

10 August 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: August 10, 2006

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200609146k.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending September 14, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No ☒

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons  
Discharging Managerial Responsibility or Connected Persons in the Ordinary  
Shares of GlaxoSmithKline plc in respect of the undermentioned persons arising

from the purchase of Ordinary Shares at a price of GBP14.79 per Ordinary Share on 11 September 2006 through the Company's ShareReward Plan ("the Plan") which the under mentioned persons entered on 5 October 2001:

Mr J S Heslop	Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)
Mr R Bondy	Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)
Mr D Learmouth	Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)
Mr A P Witty	Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

The Company and the above-mentioned persons were advised of this information on 12 September 2006.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).

S M Bicknell  
Company Secretary

14 September 2006

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: September 14, 2006

By: VICTORIA WHYTE  
-----

Mr J S Heslop Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

Mr R Bondy Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

Mr D Learmouth Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

Mr A P Witty Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

The Company and the above-mentioned persons were advised of this information on 10 November 2006.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

10 November 2006

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: November 10, 2006

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200612136k3.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending December 13, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons  
Discharging Managerial Responsibility or Connected Persons in the Ordinary  
Shares of GlaxoSmithKline plc in respect of the undermentioned persons arising  
from the purchase of Ordinary Shares at a price of GBP13.53 per Ordinary Share  
on 11 December 2006 through the Company's ShareReward Plan ("the Plan") which  
the under mentioned persons entered on 5 October 2001:

<TABLE>  
<CAPTION>  
<S>

<C>

Mr J S Heslop

Acquisition of 10 Ordinary Shares under the partnership element of  
the Plan (personal contribution)

Acquisition of 10 Ordinary Shares under the matching element of the Plan (Company contribution)

Mr R Bondy

Acquisition of 10 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 10 Ordinary Shares under the matching element of the Plan (Company contribution)

Mr D Learmouth

Acquisition of 10 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 10 Ordinary Shares under the matching element of the Plan (Company contribution)

Mr A P Witty

Acquisition of 10 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 10 Ordinary Shares under the matching element of the Plan (Company contribution)

</TABLE>

The Company and the above-mentioned persons were advised of this information on 12 December 2006.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).

S M Bicknell

Company Secretary

13 December 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: December 13, 2006

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>

</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200701056k3.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending January 05, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in interests in the Ordinary Shares of  
GlaxoSmithKline plc in respect of the under-mentioned persons, arising from the  
purchase of Ordinary Shares on 4 January 2007 under a Single Company ISA at a

price of GBP13.97 per Ordinary Share:

Mr J S Heslop

5

Mr A P Witty

4

The Company and the above named persons were advised of this information on 5 January 2007.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).

S M Bicknell  
Company Secretary

5 January 2007

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 05, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte

Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>

</DOCUMENT>



<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200701056k5.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending January 05, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons Discharging Managerial Responsibility or Connected Persons in the Ordinary Shares of GlaxoSmithKline plc in respect of the under-mentioned persons arising from the purchase of Ordinary Shares at a price of GBP13.98 per Ordinary Share on 4 January 2007 through the Company's ShareReward Plan ("the Plan") which the under-mentioned persons entered on 5 October 2001:

Mr J S Heslop Acquisition of 11 Ordinary Shares under the Dividend Reinvestment element of the Plan

Mr R Bondy Acquisition of 11 Ordinary Shares under the Dividend Reinvestment element of the Plan

Mr D Learmouth Acquisition of 11 Ordinary Shares under the Dividend Reinvestment element of the Plan

Dr D Pulman Acquisition of 6 Ordinary Shares under the Dividend Reinvestment element of the Plan

Mr C Viehbacher Acquisition of 3 Ordinary Shares under the Dividend Reinvestment element of the Plan

Mr A P Witty Acquisition of 11 Ordinary Shares under the Dividend Reinvestment element of the Plan

The Company and the above-mentioned persons were advised of this information on 5 January 2007.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).

S M Bicknell

Company Secretary

5 January 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 05, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200701056k4.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending January 05, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of an increase in interests in the Ordinary Shares of  
GlaxoSmithKline plc in respect of the personal holdings of the under-mentioned

persons at a price of GBP14.00 per Ordinary Share, following the re-investment of the dividend paid to shareholders on 4 January 2007.



Mr J S Heslop	164
Mrs P A Heslop	63
Mr R Bondy	263
Mr D Learmouth	34
Dr D Pulman	142
Mrs C Pulman	14
Mr A Witty	23
Mrs C Witty	285

The Company and the above named persons were advised of this information on 5 January 2007.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).



S M Bicknell  
Company Secretary

5 January 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 5, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte

Authorised Signatory for and on  
behalf of GlaxoSmithKline plc



</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200701116k4.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending January 11, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons  
Discharging Managerial Responsibility or Connected Persons in the Ordinary  
Shares of GlaxoSmithKline plc in respect of the undermentioned persons arising  
from the purchase of Ordinary Shares at a price of GBP13.60 per Ordinary Share

on 10 January 2007 through the Company's ShareReward Plan ("the Plan") which the under mentioned persons entered on 5 October 2001:

Mr J S Heslop

Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

Mr R Bondy

Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

Mr D Learmouth

Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

Mr A P Witty

Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

The Company and the above-mentioned persons were advised of this information on 11 January 2007.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

11 January 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 11, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>



<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200702096k3.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending February 9, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F ☒ Form 40-F ☐

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No ☒

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in interests in the Ordinary shares and American  
Depositary Shares (ADSs) of GlaxoSmithKline plc in respect of the  
under-mentioned Directors, Persons Discharging Managerial Responsibility and  
Connected Persons:-

Dr J-P Garnier      Exercise of options on 8 February 2007 over 68,411 ADSs  
granted on 24 March 1997, which would have lapsed on 23

March 2007, under the SmithKline Beecham Employee Share Option Plan 1991 at a price of \$32.09 per ADS.

The sale of 51,100 ADSs on 8 February 2007 at an average price of \$55.81.

Following this transaction Dr Garnier's total shareholding in the Company is 556,198 ADSs, which includes 248,448 ADSs that have been earned but deferred under the share programmes operated by the Company. At the price at which the above options were exercised, Dr Garnier's holding is equivalent to more than 17 times his annual basic salary.

Mr J S Heslop Purchase of 10,000 Ordinary shares on 9 February 2007 at a price of GBP14.51 per share.

Following this transaction Mr Heslop's total shareholding in the Company is 42,204 Ordinary shares. At the price at which the above shares were purchased, Mr Heslop's holding is equivalent to more than 1.5 times his annual basic salary.

Mr D Phelan Exercise of options on 8 February 2007 over 54,623 ADSs granted on 13 November 1997, which would have lapsed on 12 November 2007, under the SmithKline Beecham Employee Share Option Plan 1991 at a price of \$40.54 per ADS and over 95,000 ADSs granted on 3 December 2002 under the GlaxoSmithKline Employee Share Option Plan at a price of \$37.25 per ADS.

The sale of 149,623 ADSs on 8 February 2007 at an average price of \$55.81.

Mr D Stout Exercise of options on 8 February 2007 over 4,951 ADSs granted on 24 March 1997, which would have lapsed on 23 March 2007, under the SmithKline Beecham Employee Share Option Plan 1991 at a price of \$32.09 per ADS.

The sale of 3,475 ADSs on 8 February 2007 at an average price of \$55.87.

The Company was advised of these transactions on 8 and 9 February 2007.

This notification is in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).

S M Bicknell  
Company Secretary

9 February 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the

undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 9, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>

</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200702136k2.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending February 13, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F ☒ Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No ☒  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons  
Discharging Managerial Responsibility or Connected Persons in the Ordinary  
Shares of GlaxoSmithKline plc in respect of the undermentioned persons arising  
from the purchase of Ordinary Shares at a price of GBP14.56 per Ordinary Share  
on 9 February 2007 through the Company's ShareReward Plan ("the Plan") which the  
under mentioned persons entered on 5 October 2001:

Mr J S Heslop      Acquisition of 8 Ordinary Shares under the partnership  
                         element of the Plan (personal contribution)

                         Acquisition of 8 Ordinary Shares under the matching element  
                         of the Plan (Company contribution)

Mr R Bondy      Acquisition of 8 Ordinary Shares under the partnership  
                         element of the Plan (personal contribution)

                         Acquisition of 8 Ordinary Shares under the matching element  
                         of the Plan (Company contribution)

Mr D Learmouth      Acquisition of 8 Ordinary Shares under the partnership  
                         element of the Plan (personal contribution)

                         Acquisition of 8 Ordinary Shares under the matching element  
                         of the Plan (Company contribution)

Mr A P Witty      Acquisition of 8 Ordinary Shares under the partnership  
                         element of the Plan (personal contribution)

                         Acquisition of 8 Ordinary Shares under the matching element  
                         of the Plan (Company contribution)

The Company and the above-mentioned persons were advised of this information on  
12 February 2007.

This notification relates to a transaction notified in accordance with  
Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).

S M Bicknell  
Company Secretary

13 February 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the  
registrant has duly caused this report to be signed on its behalf by the  
undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 13, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200702236k3.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending February 23, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Completion of Performance Period ended on 31st December 2006  
in respect of awards made under the GlaxoSmithKline Performance Share Plan

The three-year performance period for the GlaxoSmithKline Performance Share Plan  
(PSP) awards made in 2003, which commenced on 1 January 2004, came to an end on  
31 December 2006.

The Remuneration Committee of the Board of GlaxoSmithKline plc (GSK) considered  
the performance achieved in respect of the PSP awards and determined that:

- the PSP awards made in 2003 would not vest for the Executive Directors  
and Corporate Executive Team (CET) members who received these awards because the  
Company's relative Total Shareholder Return (TSR) performance was below the  
median;

- the PSP awards made in 2003 to other senior executives, who have since been appointed an Executive Director or CET member, were dependent in part on TSR performance and in part on EPS performance. Half this award lapsed as GSK's TSR performance was below the median and half this award vested as GSK's EPS performance exceeded the target level for full vesting;

The following PSP awards, made in 2003, to the then Executive Directors and CET members, who are all persons discharging managerial responsibility (PDMRs), have not vested and have therefore lapsed.

<TABLE>  
<CAPTION>

Awards that have not vested and therefore lapsed <S>	Ordinary Shares <C>	ADSs <C>
Dr JP Garnier*		200,000
Mr D Stout		74,000
Mr R Bondy	77,000	
Mr D Phelan		38,500
Mr C Viehbach		38,500
Dr R Greig		25,000
Mr D Pulman	50,000	
Mr A Witty	59,000	
Mr M Dunoyer	29,000	

</TABLE>

\* Denotes an Executive Director.

Half of the PSP awards, made in 2003, to senior executives who have since been appointed Executive Directors or CET members, vested on 23 February 2007 and half of the awards lapsed, as set out in the table below.

<TABLE>  
<CAPTION>

<S>	Initial award of Shares/ADSs		Final award with 50% vesting of Shares/ADSs	
	Shares <C>	ADSs <C>	Shares <C>	ADSs <C>
Dr M Slaoui*	5,000		2,500	
Mr J Heslop*	5,000		2,500	
Mr J Clarke	14,000		7,000	
Mr D Learmouth	3,000		1,500	
Mr W Louv		2,000		1,000

</TABLE>

\* Denotes an Executive Director

The Company, the Executive Directors and other PDMRs were informed of the vesting on 23 February 2007.

S M Bicknell  
Company Secretary

23 February 2007

<TABLE>  
<CAPTION>

Enquiries:  
<S>

UK Media enquiries:

<C>	<C>
Philip Thomson	(020) 8047 5502
Alice Hunt	(020) 8047 5502
Gwenan White	(020) 8047 5502

US Media enquiries:

Nancy Pekarek	(215) 751 7709
Mary Anne Rhyne	(919) 483 2839
Patricia Seif	(215) 751 7709

European Analyst/Investor enquiries:

Anita Kidgell	(020) 8047 5542
David Mawdsley	(020) 8047 5564
Sally Ferguson	(020) 8047 5543

US Analyst/ Investor enquiries:

Frank Murdolo	(215) 751 7002
Tom Curry	(215) 751 5419

</TABLE>

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 23, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>

</DOCUMENT>



<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200702276k3.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending February 27, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F ☒ Form 40-F ☐

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No ☒

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in the interests of:

- \* Directors and Persons Discharging Managerial Responsibility in the Ordinary Shares of GlaxoSmithKline plc in respect of the undermentioned persons arising from the sale of Ordinary Shares at a price of GBP 14.37 per Ordinary Share on 27 February 2007 to meet their tax liabilities following the vesting of a Performance Share Plan award:

Mr J S Heslop	1,025
Dr M M Slaoui	740
Mr J Clarke	2,870
Mr D Learmouth	615

- \* Persons Discharging Managerial Responsibility in the American Depositary Shares (ADSs) of GlaxoSmithKline plc in respect of the undermentioned person arising from the sale of ADSs at a price of \$56.45 per ADS on 27 February 2007 to meet their tax liabilities following the vesting of a Performance Share Plan award:

Mr W Louv	325
-----------	-----

The Company, Directors, Persons Discharging Managerial Responsibility and Connected Persons were advised of these transactions on 27 February 2007.

- \* Dr M M Slaoui as a result of the grant of options and an award to his spouse, who is also employed by the company. Dr Slaoui's wife received the following awards:

Award under	ADSs
GlaxoSmithKline Performance Share Plan (PSP)	1,570
GlaxoSmithKline Share Option Plan (Option Plan)	3,570
GlaxoSmithKline Share Value Plan (SVP)	890

The award of share options was made at a subscription price of \$58.00 per ADS.

The Company and Dr Slaoui's wife were advised of these transactions on 26 February 2007.

This notification relates to a transaction notified in accordance with Disclosure Rule 3.1.4R(1) (a).

S M Bicknell  
Company Secretary

27 February 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 27, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200703126k2.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending March 12, 2007  
GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No ☒

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons  
Discharging Managerial Responsibility or Connected Persons in the Ordinary  
Shares of GlaxoSmithKline plc in respect of the undermentioned persons arising  
from the purchase of Ordinary Shares at a price of GBP14.35 per Ordinary Share  
on 9 March 2007 through the Company's ShareReward Plan ("the Plan") which the  
under mentioned persons entered on 5 October 2001:

<TABLE>  
<CAPTION>  
<S>

<C>

Mr J S Heslop

Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

Mr R Bondy

Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

Mr D Learmouth

Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

Mr A P Witty

Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

</TABLE>

The Company and the above-mentioned persons were advised of this information on 12 March 2007.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).

S M Bicknell  
Company Secretary

12 March 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

By: VICTORIA WHYTE

-----  
Victoria Whyte

Authorized Signatory for and on  
behalf of GlaxoSmithKline plc

Date: March 12, 2007

</TEXT>

</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200704136k2.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending April 13, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No ☒

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons  
Discharging Managerial Responsibility or Connected Persons in the Ordinary  
Shares of GlaxoSmithKline plc in respect of the under-mentioned persons arising

from the purchase of Ordinary Shares at a price of GBP 14.12 per Ordinary Share on 12 April 2007 through the Company's ShareReward Plan ("the Plan") which the under-mentioned persons entered on 5 October 2001:

Mr J S Heslop	Acquisition of 12 Ordinary Shares under the Dividend Reinvestment element of the Plan
Mr R Bondy	Acquisition of 12 Ordinary Shares under the Dividend Reinvestment element of the Plan
Mr D Learmouth	Acquisition of 12 Ordinary Shares under the Dividend Reinvestment element of the Plan
Dr D Pulman	Acquisition of 7 Ordinary Shares under the Dividend Reinvestment element of the Plan
Mr C Viehbacher	Acquisition of 3 Ordinary Shares under the Dividend Reinvestment element of the Plan
Mr A P Witty	Acquisition of 12 Ordinary Shares under the Dividend Reinvestment element of the Plan

The Company and the above-mentioned persons were advised of this information on 13 April 2007.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

13 April 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: April 13, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200704136k.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending April 13, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F ☒ Form 40-F ☐  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes ☐ No ☒  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons  
Discharging Managerial Responsibility or Connected Persons in the Ordinary  
Shares of GlaxoSmithKline plc in respect of the undermentioned persons arising  
from the purchase of Ordinary Shares at a price of GBP 14.12 per Ordinary Share  
on 12 April 2007 through the Company's ShareReward Plan ("the Plan") which the  
under mentioned persons entered on 5 October 2001:



Mr J S Heslop Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

Mr R Bondy Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

Mr D Learmouth Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

Mr A P Witty Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

The Company and the above-mentioned persons were advised of this information on 13 April 2007.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

13 April 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: April 13, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200704166k4.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending April 16, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F ☒ Form 40-F ☐  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes ☐ No ☒  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in interests in the Ordinary Shares of  
GlaxoSmithKline plc in respect of the under-mentioned persons, arising from the  
purchase of Ordinary Shares on 12 April 2007 under a Single Company ISA at a  
price of GBP14.10 per Ordinary Share:

Mr J S Heslop

6

Mr A P Witty

5

The Company and the above named persons were advised of this information on 16 April 2007.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

16 April 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: April 16, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200704166k5.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending April 16, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of an increase in interests in the Ordinary Shares of  
GlaxoSmithKline plc in respect of the personal holdings of the under-mentioned  
persons at a price of GBP14.23 per Ordinary Share, following the re-investment  
of the dividend paid to shareholders on 12 April 2007.

Mr J S Heslop

190

Mrs P A Heslop	72
Mr R Bondy	326
Mr D Learmouth	39
Dr D Pulman	135
Mrs C Pulman	45
Mr A P Witty	23
Mrs C Witty	330

The Company and the above named persons were advised of this information on 16 April 2007.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

16 April 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: April 16, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200705116k.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending May 11, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons

Discharging Managerial Responsibility or Connected Persons in the Ordinary Shares of GlaxoSmithKline plc in respect of the undermentioned persons arising from the purchase of Ordinary Shares at a price of GBP14.28 per Ordinary Share on 10 May 2007 through the Company's ShareReward Plan ("the Plan") which the under mentioned persons entered on 5 October 2001:

Mr J S Heslop	Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)
Mr R Bondy	Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)
Mr D Learmouth	Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)
Mr A P Witty	Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)
	Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

The Company and the above-mentioned persons were advised of this information on 11 May 2007.

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).

S M Bicknell  
Company Secretary

11 May 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: May 11, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>





## **EXHIBIT 46C**

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200511076k4.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending November 7, 2005

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held  
within the US Retirement Savings Plan ("The Plan"), which is notionally held in  
GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline  
plc and the under-mentioned persons on 7 November 2005 of an increase in the

notional allocation of Ordinary Share ADRs on 3 November 2005 at a price of \$52.43 per share:-

Dr J P Garnier	34
Dr T Yamada	12
Dr W Calhoun	6
Mr D Phelan	108
Dr D Pulman	1
Mr D Stout	16
Mr C Viehbacher	2
Mr J Ziegler	5
Dr R Greig	48

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).

S M Bicknell  
Company Secretary  
7 November 2005

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: November 7, 2005

By: SIMON BICKNELL

-----  
Simon Bicknell  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>

</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200601096k4.txt  
<DESCRIPTION>DIRECTIOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending January 09, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

The Administrators of the GlaxoSmithKline Executive Supplemental Savings Plan  
notified the Company and the under-mentioned persons on 9 January 2006 of  
changes in their interests in Ordinary Share ADRs arising from an increase in

their interests under the Annual Investment Plan feature following the re-investment of the dividend paid to shareholders on 5 January 2006 at a price of \$51.95 per share:-

Mr W Calhoun	271.944
Dr J P Garnier	263.833
Mr D Stout	216.461
Dr T Yamada	169.762
Mr J Ziegler	69.733

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

9 January 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 09, 2006

By: VICTORIA LLEWELLYN

-----  
Victoria Llewellyn  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>

</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200601176k5.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending January 17, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held  
within the US Retirement Savings Plan ("The Plan"), which is notionally held in  
GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline  
plc and the under-mentioned persons on 17 January 2006 of an increase in the

Dr J-P Garnier	297.426
Dr F Calhoun	306.570
Dr D Pulman	16.025
Mr D Stout	244.023

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b) .

S M Bicknell

Company Secretary

10 October 2006

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: October 10, 2006

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200611086k2.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending November 08, 2006

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held  
within the US Retirement Savings Plan ("The Plan"), which is notionally held in  
GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline  
plc and the under-mentioned persons on 8 November 2006 of an increase in the  
notional allocation of Ordinary Share ADRs on 2 November 2006 at a price of  
\$53.93 per share:-



Dr JP Garnier	54
Dr MM Slaoui	1
Dr F Calhoun	11
Dr R Greig	68
Mr D Phelan	162
Dr D Pulman	11
Mr D Stout	27
Mr C Viehbacher	4

Following a re-valuation of the cash element of the notional investment held within the Plan, which is notionally held in GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline plc and the under-mentioned persons on 7 November 2006 of an increase in the notional allocation of Ordinary Share ADRs on 3 November 2006 at a price of \$53.30 per share:-

Dr MM Slaoui	2
Dr R Greig	3

These notifications relate to transactions notified in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).

S M Bicknell  
Company Secretary

8 November 2006

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: November 08, 2006

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200701056k6.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending January 05, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

The Administrators of the GlaxoSmithKline Executive Supplemental Savings Plan notified the Company and the under-mentioned persons on 5 January 2007 of changes in their interests in Ordinary Share ADRs arising from an increase in their interests under the Annual Investment Plan feature following the re-investment of the dividend paid to shareholders on 4 January 2007 at a price of \$54.72 per share:-

Dr JP Garnier	327.53
Dr F Calhoun	337.60
Dr D Pulman	17.65
Mr D Stout	268.72

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b) .

S M Bicknell  
Company Secretary

5 January 2007  
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 05, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte

Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200701166k.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending January 16, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F ☒ Form 40-F ☐

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No ☒

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held  
within the US Retirement Savings Plan ("The Plan"), which is notionally held in

GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline plc and the under-mentioned persons on 15 January 2007 of an increase in the notional allocation of Ordinary Share ADRs on 12 January 2007 at a price of \$53.75 per share:-

Dr J-P Garnier	92
Dr M M Slaoui	8
Mrs C Bruck Slaoui	2
Dr F Calhoun	17
Dr R G Greig	17
Mr D Phelan	20
Dr D Pulman	6
Mr D Stout	44
Mr C Viehbacher	8

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).

S M Bicknell  
Company Secretary

16 January 2007

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 16, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200701296k4.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending January 29, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held

within the US Retirement Savings Plan ("The Plan"), which is notionally held in GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline plc and the under-mentioned person(s) on 29 January 2007 of an increase in the notional allocation of Ordinary Share ADRs on 26 January 2007 at a price of \$54.61 per share:-

Dr J P Garnier	91
Dr M M Slaoui	8
Mrs C Bruck Slaoui	3
Dr F Calhoun	17
Dr R G Greig	20
Mr D Phelan	21
Dr D Pulman	7
Mr D Stout	43
Mr C Viehbacher	8

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

29 January 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 29, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte

Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>

</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200702096k3.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending February 9, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F ☒ Form 40-F ☐  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes ☐ No ☒  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

I give below details of changes in interests in the Ordinary shares and American  
Depositary Shares (ADSs) of GlaxoSmithKline plc in respect of the  
under-mentioned Directors, Persons Discharging Managerial Responsibility and  
Connected Persons:-

Dr J-P Garnier	Exercise of options on 8 February 2007 over 68,411 ADSs granted on 24 March 1997, which would have lapsed on 23
----------------	--



March 2007, under the SmithKline Beecham Employee Share Option Plan 1991 at a price of \$32.09 per ADS.

The sale of 51,100 ADSs on 8 February 2007 at an average price of \$55.81.

Following this transaction Dr Garnier's total shareholding in the Company is 556,198 ADSs, which includes 248,448 ADSs that have been earned but deferred under the share programmes operated by the Company. At the price at which the above options were exercised, Dr Garnier's holding is equivalent to more than 17 times his annual basic salary.

Mr J S Heslop Purchase of 10,000 Ordinary shares on 9 February 2007 at a price of GBP14.51 per share.

Following this transaction Mr Heslop's total shareholding in the Company is 42,204 Ordinary shares. At the price at which the above shares were purchased, Mr Heslop's holding is equivalent to more than 1.5 times his annual basic salary.

Mr D Phelan Exercise of options on 8 February 2007 over 54,623 ADSs granted on 13 November 1997, which would have lapsed on 12 November 2007, under the SmithKline Beecham Employee Share Option Plan 1991 at a price of \$40.54 per ADS and over 95,000 ADSs granted on 3 December 2002 under the GlaxoSmithKline Employee Share Option Plan at a price of \$37.25 per ADS.

The sale of 149,623 ADSs on 8 February 2007 at an average price of \$55.81.

Mr D Stout Exercise of options on 8 February 2007 over 4,951 ADSs granted on 24 March 1997, which would have lapsed on 23 March 2007, under the SmithKline Beecham Employee Share Option Plan 1991 at a price of \$32.09 per ADS.

The sale of 3,475 ADSs on 8 February 2007 at an average price of \$55.87.

The Company was advised of these transactions on 8 and 9 February 2007.

This notification is in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).

S M Bicknell  
Company Secretary

9 February 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the

undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 9, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200702136k6.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending February 13, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held  
within the US Retirement Savings Plan ("The Plan"), which is notionally held in  
GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline  
plc and the under-mentioned persons on 12 February 2007 of an increase in the  
notional allocation of Ordinary Share ADRs on 9 February 2007 at a price of

\$56.38 per share:-	
Dr JP Garnier	88
Dr M M Slaoui	62
Mrs C Bruck Slaoui	2
Dr R G Greig	18
Mr W Louv	4
Mr D Phelan	19
Dr D Pulman	6
Mr D Stout	42
Mr C Viehbacher	7

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).

S M Bicknell

Company Secretary

13 February 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 13, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>

</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200702166k6.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending February 16, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held  
within the US Retirement Savings Plan ("The Plan"), which is notionally held in

GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline plc and the under-mentioned persons on 16 February 2007 of an increase in the notional allocation of Ordinary Share ADRs on 15 February 2007 at a price of \$57.65 per share:-

Dr JP Garnier	63
Dr M M Slaoui	2
Dr R G Greig	76
Mr W Louv	5
Mr D Phelan	184
Dr D Pulman	13
Mr D Stout	32
Mr C Viehbacher	4

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

16 February 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 16, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200703056k4.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending March 05, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F ☒ Form 40-F ☐

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No ☒

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held  
within the US Retirement Savings Plan ("The Plan"), which is notionally held in

GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline plc and the under-mentioned persons on 2 March 2007 of:

(i) An increase in the notional allocation of Ordinary Share ADRs on 23 February 2007 at a price of \$56.92 per share:-

Dr JP Garnier	35
Dr M M Slaoui	7
Mrs C Bruck Slaoui	3
Dr R G Greig	21
Mr W Louv	5
Dr D Pulman	6
Mr D Stout	42
Mr C Viehbacher	8

(ii) A decrease in the notional allocation of Ordinary Share ADRs on 9 February 2007 at a price of \$56.38 per share:-

Dr M M Slaoui	54
---------------	----

(iii) A decrease in the notional allocation of Ordinary Share ADRs on 15 February 2007 at a price of \$57.65 per share:-

Dr M M Slaoui	1
---------------	---

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell

Company Secretary

5 March 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: March 05, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc



</TEXT>  
</DOCUMENT>



<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200703136k4.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending March 13, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held  
within the US Retirement Savings Plan ("The Plan"), which is notionally held in

GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline plc and the under-mentioned persons on 13 March 2007 of:

- (i) An increase in the notional allocation of Ordinary Share ADRs on 9 March 2007 at a price of \$55.59 per share:-

Dr M M Slaoui	50
Mrs C Bruck Slaoui	38
Dr R G Greig	177
Mr W Louv	64
Dr D Pulman	56
Mr D Stout	122
Mr C Viehbacher	50

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).

S M Bicknell  
Company Secretary

13 March 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: March 13, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200704136k4.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending April 13, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F ☒ Form 40-F ☐  
--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes ☐ No ☒  
--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

The Administrators of the GlaxoSmithKline Executive Supplemental Savings Plan notified the Company and the under-mentioned persons on 13 April 2007 of changes in their interests in Ordinary Share ADRs arising from an increase in their interests under the Annual Investment Plan feature following the re-investment of the dividend paid to shareholders on 12 April 2007 at a price of \$57.07 per share:-

Dr JP Garnier	387.74
Dr D Pulman	20.89
Mr D Stout	318.12

This notification relates to a transaction notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell  
Company Secretary

13 April 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: April 13, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>  
</DOCUMENT>

<DOCUMENT>  
<TYPE>6-K  
<SEQUENCE>1  
<FILENAME>gsk200705096k2.txt  
<DESCRIPTION>DIRECTOR/PDMR SHAREHOLDING  
<TEXT>

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending May 09, 2007

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F  
or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial  
Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held  
within the US Retirement Savings Plan ("The Plan"), which is notionally held in  
GSK Ordinary Share ADRs, the Administrators of the Plan notified GlaxoSmithKline  
plc and the under-mentioned persons on 9 May 2007 of:

(i) . An increase in the notional allocation of Ordinary Share ADRs on 3 May 2007

at a price of \$57.44 per share:-

Dr JP Garnier	59
Dr M M Slaoui	1
Mrs C Bruck Slaoui	1
Dr R G Greig	72
Mr W C Louv	5
Dr D Pulman	12
Mr D M Stout	29
Mr C Viehbacher	4

The Administrators of the Plan further notified GlaxoSmithKline plc and the under-mentioned persons on 9 May 2007 of

- (i) An increase in the notional allocation of Ordinary Share ADRs on 4 May 2007 at a price of \$57.90 per share:-

Mrs C Bruck Slaoui	3
Dr R G Greig	1

This notification relates to transactions notified in accordance with Disclosure Rules 3.1.4R(1) (a) and 3.1.4R(1) (b).

S M Bicknell

Company Secretary

9 May 2007

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: May 09, 2007

By: VICTORIA WHYTE

-----  
Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc

</TEXT>

</DOCUMENT>